Parvinder Thiara
Direktor/Vorstandsmitglied bei ZURA BIO LIMITED
Vermögen: 1 Mio $ am 30.04.2024
Profil
Parvinder Singh Thiara is the founder.
He founded Athanor Capital LP in 2017, where he holds the title of CIO & Chief Compliance Officer.
Currently, Mr. Thiara holds the position of Director at Tourmaline Sub, Inc. since 2022, Independent Director at Tourmaline Bio, Inc. since 2023, and Independent Director at Zura Bio Ltd.
since 2023.
In the past, he worked as a Senior Vice President at D.E.
Shaw & Co., Inc. Mr. Thiara has a graduate degree from the University of Oxford and an undergraduate degree from Harvard College.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
0,32% | 25.10.2023 | 82 782 ( 0,32% ) | 1 Mio $ | 30.04.2024 |
Aktive Positionen von Parvinder Thiara
Unternehmen | Position | Beginn |
---|---|---|
ZURA BIO LIMITED | Direktor/Vorstandsmitglied | 01.06.2023 |
Athanor Capital LP
Athanor Capital LP Investment ManagersFinance Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles. | Gründer | 01.01.2017 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Direktor/Vorstandsmitglied | 01.09.2022 |
Ehemalige bekannte Positionen von Parvinder Thiara
Unternehmen | Position | Ende |
---|---|---|
D.E. Shaw & Co., Inc.
D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Corporate Officer/Principal | - |
Ausbildung von Parvinder Thiara
University of Oxford | Graduate Degree |
Harvard College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ZURA BIO LIMITED | Health Technology |
Private Unternehmen | 3 |
---|---|
D.E. Shaw & Co., Inc.
D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Finance |
Athanor Capital LP
Athanor Capital LP Investment ManagersFinance Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles. | Finance |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |